<?xml version="1.0" encoding="UTF-8"?>
<ref id="B41-vaccines-07-00074">
 <label>41.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Moldt</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Rakasz</surname>
    <given-names>E.G.</given-names>
   </name>
   <name>
    <surname>Schultz</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Chan-Hui</surname>
    <given-names>P.Y.</given-names>
   </name>
   <name>
    <surname>Swiderek</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Weisgrau</surname>
    <given-names>K.L.</given-names>
   </name>
   <name>
    <surname>Piaskowski</surname>
    <given-names>S.M.</given-names>
   </name>
   <name>
    <surname>Bergman</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Watkins</surname>
    <given-names>D.I.</given-names>
   </name>
   <name>
    <surname>Poignard</surname>
    <given-names>P.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo</article-title>
  <source>Proc. Natl. Acad. Sci. USA</source>
  <year>2012</year>
  <volume>109</volume>
  <fpage>18921</fpage>
  <lpage>18925</lpage>
  <pub-id pub-id-type="doi">10.1073/pnas.1214785109</pub-id>
  <pub-id pub-id-type="pmid">23100539</pub-id>
 </element-citation>
</ref>
